BIOMAT Database Logo BIOMAT Database Logo

The mechanisms of activation of normal human serum complement by Escherichia coli strains with K1 surface antigen. 2006

G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Institute of Genetics and Microbiology University of Wroclaw, Poland. gbploskonska@poczta.onet.pl

Ten E. coli K1 strains isolated from the urine of children with urinary tract infections were sensitive to the bactericidal action of normal human serum (NHS). The role of the particular mechanisms of complement activation was determined in the process of killing these strains, showing variable sensitivity to the bactericidal action of NHS; three mechanisms of activation of human complement were observed. Important role of alternative pathway activation in the bactericidal action of NHS against E. coli K1 strains independent of the classical and lectin pathways was not established.

UI MeSH Term Description Entries
D001770 Blood Bactericidal Activity The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST. Activities, Blood Bactericidal,Activity, Blood Bactericidal,Bactericidal Activities, Blood,Bactericidal Activity, Blood,Blood Bactericidal Activities
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell

Related Publications

G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
[Interaction of cefotaxime and normal human serum in the bacteriocidal process against strains of Escherichia coli producing surface K1 antigen].
January 1993, Medycyna doswiadczalna i mikrobiologia,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
The sensitivity of escherichia coli strains with K1 surface antigen and rods without this antigen to the bactericidal effect of serum.
January 2004, Folia microbiologica,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Synergistic effect of cefotaxime and normal human serum on bactericidal activity against urinary strains of Escherichia coli with capsular antigen K1.
January 1993, Acta microbiologica Polonica,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Interaction of E. coli strains with human serum: lack of relationship to K1 antigen.
December 1976, The Journal of pediatrics,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Prevalence of genes encoding virulence factors among Escherichia coli with K1 antigen and non-K1 E. coli strains.
October 2012, Journal of medical microbiology,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Interaction of human complement proteins with serum-sensitive and serum-resistant strains of Escherichia coli.
July 1984, Molecular immunology,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Identification of Escherichia coli K1 antigen.
August 1984, Journal of clinical microbiology,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Complement pathway activity in the opsonization of cefotaxime-treated Escherichia coli by normal human serum.
July 1988, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
Susceptibility of Escherichia coli with capsular antigen K1 isolated from urinary tract infection on the joint action of cefotaxime and normal human serum.
January 1994, Nephron,
G Bugla-Płoskońska, and A Cisowska, and K Karpińska, and S Jankowski, and W Doroszkiewicz
[The occurrence of Escherichia coli with K1 surface antigen in pregnant women and in newborns].
January 2010, Medycyna doswiadczalna i mikrobiologia,
Copied contents to your clipboard!